11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

Inclusion Criteria:

Age: Patients must be >=18 years of age
Diagnosis: Patients must have a diagnosis of prostate cancer by histologic verification and a hypoechoic lesion seen on ultrasound.
Disease Status: Unfavorable intermediate to high-risk prostate cancer, per the Cancer of the Prostate Risk Assessment Score (CAPRA) (CAPRA 5-10)
Karnofsky Performance Status >=70
Metastatic workup: Whole Body Sodium Fluoride (NaF) PET/CT or 99mTc Bone Scan
Planned to undergo radical prostatectomy and extended pelvic lymph node dissection
Adequate bone marrow and organ function defined as follows:
Adequate bone marrow function:
Leukocytes >= 3,000/microliter (mcL)
Absolute Neutrophil Count >= 1,500/mcL
Platelets >= 100,000/mcL
Adequate hepatic function:
Total bilirubin - within normal institutional limits
Aspartate aminotransferase (AST)/ serum glutamic-oxaloacetic transaminase (SGOT) <= 2.5 X institutional upper limit of normal
Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <= 2.5 X institutional upper limit of normal
Adequate renal function:
Creatinine - within normal institutional limits OR
Creatinine clearance >= 60 mL/min/ 1.73m2 for patients with creatinine levels above institutional normal
Ability to understand a written informed consent document, and the willingness to sign it

Exclusion Criteria:

Participation would significantly delay the scheduled standard of care therapy
Karnofsky performance status of < 60
Inadequate venous access
Administered a radioisotope within 5 physical half lives prior to study enrollment
Have a medical condition or other circumstances which, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the study.